News | August 10, 2024
Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Shares and American Depositary Shares of Olink for $26.00 per Share
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Combined entity is better positioned to compete in increasingly competitive generics industry
Subscribe To Our Newsletter & Stay Updated
